胰蛋白酶、菠萝蛋白酶和芦丁联合预处理对症状性不可逆性牙髓炎麻醉成功率和术后疼痛的影响:一项随机对照试验
这项随机三盲平行臂临床试验纳入124例下颌磨牙症状性不可逆性牙髓炎患者,比较胰蛋白酶/菠萝蛋白酶/芦丁组合(TBR)、双氯芬酸钾、泼尼松龙和安慰剂预处理对下牙槽神经阻滞麻醉成功率及术后疼痛的影响。结果显示TBR组和泼尼松龙组麻醉成功率显著高于安慰剂组,TBR组术后72小时内疼痛评分显著低于安慰剂组,且TBR疗效与泼尼松龙相当。
要点
- TBR预处理可显著提高症状性不可逆性牙髓炎下颌磨牙IANB麻醉成功率。
- TBR组术后72小时内疼痛评分显著低于安慰剂组。
- TBR疗效与泼尼松龙相当,或可替代 corticosteroids 或NSAIDs。
核心结论
- TBR联合预处理显著提高症状性不可逆性牙髓炎下颌磨牙IANB成功率并减轻术后疼痛,疗效与泼尼松龙相当。
研究设计与样本
- 随机、三盲、平行臂临床试验,124例健康成人下颌单颗磨牙症状性不可逆性牙髓炎患者按1:1:1:1随机分为四组(每组n=31)。
主要发现
- TBR组麻醉成功率87.1%,泼尼松龙组83.9%,均显著高于安慰剂组35.5%(p<0.001)。
- TBR组相比安慰剂组成功率的RR为2.45(99.17% CI: 1.26, 4.77)。
- 双氯芬酸组相比TBR组成功率的RR为0.59(99.17% CI: 0.36, 0.97)。
- TBR组术后72小时内疼痛评分显著低于安慰剂组(p<0.05)。
- 补救镇痛药摄入量(p=0.320)和不良事件报告无显著差异。
关键数值与推荐
- 麻醉成功定义为无痛或轻度疼痛(NRS≤3)下完成牙髓治疗。
- 预处理方案:TBR组胰蛋白酶100 mg/菠萝蛋白酶90 mg/芦丁48 mg;双氯芬酸钾50 mg;泼尼松龙20 mg;安慰剂。
- 预处理1小时后行标准IANB(1.8 mL 4%阿替卡因,1:100 000肾上腺素)。
临床怎么用
- 对于症状性不可逆性牙髓炎下颌磨牙,可考虑术前1小时给予TBR联合预处理以提高IANB成功率并减轻术后疼痛。
局限性
- 单中心研究,仅纳入下颌磨牙,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Achieving profound pulpal anaesthesia in patients with symptomatic irreversible pulpitis (SIP) remains a significant clinical challenge, as standard inferior alveolar nerve blocks (IANB) frequently fail due to localized inflammation. This clinical trial evaluated the effect of preoperative systemic enzyme therapy [trypsin, bromelain, and rutoside (TBR)] on anaesthetic success and postoperative pain in patients with symptomatic irreversible pulpitis. METHODOLOGY: In this randomized, triple-blind, parallel-arm clinical trial, 124 healthy adults with SIP in a single mandibular molar were randomly allocated (1:1:1:1) to four groups (n = 31): Group FG (trypsin 100 mg/bromelain 90 mg/rutoside 48 mg), Group DF (diclofenac potassium 50 mg), Group PD (prednisolone 20 mg), or Group PB (placebo). One hour after premedication, a standard IANB (1.8 mL 4% articaine, 1:100 000 epinephrine) was administered. The primary outcome was anaesthetic success, defined as the ability to complete endodontic procedures with no or mild pain (NRS ≤ 3). Secondary outcomes included postoperative pain intensity (NRS 0-10) recorded at 6, 12, 24, 48, 72 h, and 7 days, and rescue analgesic intake. RESULTS: Data of all 124 enrolled patients was analysed. Premedication significantly influenced IANB success (p < 0.001). Group FG (87.1%) and group PD (83.9%) achieved significantly higher success rates than group PB (35.5%); the RR of success for group FG compared to PB was 2.45 (99.17% CI: 1.26, 4.77), and for group PB compared to PD was 0.44 (99.17% CI: 0.22, 0.87). Group FG also showed significantly higher success than group DF RR of success for group DF compared to FG was 0.59 (99.17% CI: 0.36, 0.97). Group FG demonstrated significantly lower postoperative pain scores through 72 h compared to the placebo (p < 0.05). There were no significant differences in rescue analgesic intake (p = 0.320) or reported adverse events. CONCLUSIONS: Premedication with the TBR combination significantly improved the success rate of IANB and reduced postoperative pain in mandibular molars with SIP with clinical efficacy comparable to prednisolone. CLINICAL IMPLICATIONS: Systemic enzyme therapy may offer a viable, natural, and potentially safer alternative to corticosteroids or NSAIDs for enhancing pulpal anaesthesia and managing postoperative pain in symptomatic irreversible pulpitis. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06298383.
引用
- Nasr M, Hassan N. The Effect of Premedication With Trypsin, Bromelain and Rutoside Combination on Anaesthetic Success and Postoperative Pain in Patients With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial. Int Endod J. 2026. PMID: 42473278. doi:10.1111/iej.70231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。